There are many venture capitalists around the world that make headlines on a regular occasion. These entrepreneurs are responsible for many advances in various industries on a global scale. One individual who is especially well known to headlines is Jim Tananbaum. Jim Tananbaum is a well experienced venture capitalist and an innovative leader in the healthcare industry.
Jim is the CEO and founder of Foresite Capital. Foresite Capital is venture capitalist company responsible for providing funding for companies providing innovative technological advances in the healthcare industry. In fact, Foresite Capital and Mr. Tananbaum were both mentioned in recent articles that were published highlighting the recent funding of the company Mindstrong Health. One article was published on PatientDaily’s website on June 25, 2017. The title of this article is; “Start Up Health Tech Firm Mindstong Health Secures $14 million in Funding.” The article was written by Ruth de Jaurequi. The other recent article was published on Massdevice.com. It was written by Fink Densford and is titled; “Neuropsych Treatment and Diagnosis Platform dev Mindstrong Health Raises $14M in Series A.”
Mindstrong Health is a small company that was founded by Paul Dagum. The goal of Mindstrong Health is to create a device that allows smartphones to help diagnose and treat several types of mental health issues. Foresite Capital is mentioned because they are the leading investors in the company. ARCH Venture Partners Optum Ventures, and One Mind Brain Impact Fund also provided substantial funding amounts to Mindstrong Health.
Jim Tananbaum has, in fact, been in the healthcare investment funding industry for over 25 years. He has been the head of several companies including Prospect Venture Partners, Seirra Ventures, and Theravance (THRX). Mr. Tananbaum, through Foresite Capital, is also an investor in several pharmaceutical companies including; Amira Pharmaceuticals, Amerigroup, and Jazz Pharmaceuticals. He is also on the board of directors for Tarsa Therapeutics.
For more info, visit Jim Tananbaum’s Linked In page.